Mirum Pharmaceuticals, Inc.
MIRMNASDAQHealthcare● Active
$93.48
+$0.99(+1.07%)
Market Cap$4.7B
P/E Ratio—
52W High$114.99
52W Low$43.5
Mirum Pharmaceuticals, Inc. (MIRM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MIRM · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.52B | $0.34B | $0.19B | $0.08B | $0.02B |
| Cost of Revenue | $0.10B | $0.08B | $0.05B | $0.01B | $0.00B |
| Gross Profit | $0.42B | $0.26B | $0.14B | $0.06B | $0.02B |
| Gross Margin %(computed) | 80.71% | 75.77% | 74.76% | 83.94% | 90.06% |
| Operating Expenses | |||||
| R&D Expenses | $0.19B | $0.14B | $0.10B | $0.11B | $0.13B |
| G&A Expenses | $0.00B | $0.19B | $0.14B | $0.00B | $0.05B |
| Total Operating Expenses | $0.44B | $0.34B | $0.25B | $0.20B | $0.19B |
| Operating Income | ($0.02B) | ($0.09B) | ($0.11B) | ($0.13B) | ($0.17B) |
| Operating Margin %(computed) | -4.25% | -26.00% | -58.57% | -170.28% | -906.12% |
| Interest Income | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.02B | $0.02B | $0.02B |
| Income Before Tax | ($0.02B) | ($0.09B) | ($0.16B) | ($0.14B) | ($0.08B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | ($0.01B) | $0.00B |
| Net Income | ($0.02B) | ($0.09B) | ($0.16B) | ($0.14B) | ($0.08B) |
| Net Margin %(computed) | -4.48% | -26.10% | -87.68% | -176.05% | -438.85% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.47 | $-1.85 | $-4.00 | $-4.01 | $-2.77 |
| Wtd Avg Shares | 0.05B | 0.05B | 0.04B | 0.03B | 0.03B |
| EBITDA | $0.02B | ($0.05B) | ($0.14B) | ($0.12B) | ($0.07B) |
| EBITDA Margin %(computed) | 3.30% | -14.54% | -73.23% | -159.42% | -341.66% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Mirum Pharmaceuticals, Inc. data
About Mirum Pharmaceuticals, Inc. (MIRM) Income Statement
Mirum Pharmaceuticals, Inc. (MIRM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, MIRM reported revenue of $0.52B, gross profit of $0.42B (gross margin 80.71%), and net income of ($0.02B) — a net profit margin of -4.48%.
Frequently asked questions
MIRM · 4 questionsMirum Pharmaceuticals, Inc. (MIRM) reported revenue of $0.52B for 2025, up 54.7% year-over-year.
MIRM revenueMIRM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08